NasdaqGS - Delayed Quote • USD
Unity Biotechnology, Inc. (UBX)
At close: 4:00 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
--
236.0000
4,784.0000
--
Operating Expense
39,065.0000
39,065.0000
57,808.0000
61,449.0000
91,334.0000
Operating Income
-39,065.0000
-39,065.0000
-57,572.0000
-56,665.0000
-91,334.0000
Net Non Operating Interest Income Expense
422.0000
422.0000
-2,338.0000
-3,077.0000
-96.0000
Other Income Expense
-1,217.0000
-1,217.0000
15,441.0000
-983.0000
-2,414.0000
Pretax Income
-39,860.0000
-39,860.0000
-44,469.0000
-60,725.0000
-93,844.0000
Net Income Common Stockholders
-39,860.0000
-39,860.0000
-44,469.0000
-60,725.0000
-93,844.0000
Diluted NI Available to Com Stockholders
-39,860.0000
-39,860.0000
-44,469.0000
-60,725.0000
-93,844.0000
Basic EPS
-3.20
-2.70
-4.68
-10.88
-18.45
Diluted EPS
-3.20
-2.70
-4.68
-10.88
-18.45
Basic Average Shares
14,382.8780
14,773.6120
9,494.4210
5,581.5870
5,086.4890
Diluted Average Shares
14,382.8780
14,773.6120
9,494.4210
5,581.5870
5,086.4890
Total Operating Income as Reported
-44,667.0000
-44,667.0000
-57,572.0000
-56,665.0000
-93,930.0000
Total Expenses
39,065.0000
39,065.0000
57,808.0000
61,449.0000
91,334.0000
Net Income from Continuing & Discontinued Operation
-39,860.0000
-39,860.0000
-44,469.0000
-60,725.0000
-93,844.0000
Normalized Income
-40,473.0000
-40,473.0000
-61,312.0000
-60,725.0000
-91,248.0000
Interest Income
2,874.0000
2,874.0000
1,220.0000
100.0000
1,196.0000
Interest Expense
2,452.0000
2,452.0000
3,558.0000
3,177.0000
1,292.0000
Net Interest Income
422.0000
422.0000
-2,338.0000
-3,077.0000
-96.0000
EBIT
-37,408.0000
-37,408.0000
-40,911.0000
-57,548.0000
-92,552.0000
EBITDA
-36,226.0000
-36,226.0000
-38,731.0000
-54,668.0000
-89,103.0000
Reconciled Depreciation
1,182.0000
1,182.0000
2,180.0000
2,880.0000
3,449.0000
Net Income from Continuing Operation Net Minority Interest
-39,860.0000
-39,860.0000
-44,469.0000
-60,725.0000
-93,844.0000
Total Unusual Items Excluding Goodwill
613.0000
613.0000
16,843.0000
--
-2,596.0000
Total Unusual Items
613.0000
613.0000
16,843.0000
--
-2,596.0000
Normalized EBITDA
-36,839.0000
-36,839.0000
-55,574.0000
-54,668.0000
-86,507.0000
12/31/2020 - 5/3/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
MRSN Mersana Therapeutics, Inc.
2.9400
+3.16%
ENVB Enveric Biosciences, Inc.
0.9000
-1.91%
ADXS Ayala Pharmaceuticals, Inc.
0.5550
+0.91%
SNGX Soligenix, Inc.
0.4150
-2.81%
ALXO ALX Oncology Holdings Inc.
16.86
-0.06%
LCTX Lineage Cell Therapeutics, Inc.
1.1300
+1.80%
VYNE VYNE Therapeutics Inc.
2.5000
+1.21%
KRBP Kiromic BioPharma, Inc.
3.0800
+13.65%
NMRA Neumora Therapeutics, Inc.
9.15
+0.99%
SEEL Seelos Therapeutics, Inc.
0.2910
+1.89%